References
- Bramwell VH, Doig GS, Tuck AB, et al (2006). Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res, 12, 3337-43. https://doi.org/10.1158/1078-0432.CCR-05-2354
- Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. https://doi.org/10.1002/hep.24199
- Chen RX, Xia YH, Cui JF, et al (2010). Osteopontin, a single marker for predicting the prognosis of patients with tumornode-metastasis stage I hepatocellular carcinoma after surgical resection. J Gastroenterol Hepatol, 25, 1435-42. https://doi.org/10.1111/j.1440-1746.2010.06277.x
- Cheng J, Wang W, Sun C, et al (2014). Meta-analysis of the prognostic and diagnostic significance of serum/ plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol, 48, 806-14. https://doi.org/10.1097/MCG.0000000000000018
- Chittmittrapap S, Chieochansin T, Chaiteerakij R, et al (2013). Prevalence of aflatoxin induced p53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg). Asian Pac J Cancer Prev, 14, 7675-9. https://doi.org/10.7314/APJCP.2013.14.12.7675
- Debruyne EN, Delanghe JR (2008). Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications. Clin Chim Acta, 395, 19-26. https://doi.org/10.1016/j.cca.2008.05.010
- Denhardt DT, Giachelli CM, Rittling SR (2001). Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol, 41, 723-49. https://doi.org/10.1146/annurev.pharmtox.41.1.723
- Dong QZ, Zhang XF, Zhao Y, et al (2013). Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology, 57, 1024-34. https://doi.org/10.1002/hep.26103
- El-Serag HB (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142, 1264-73 . https://doi.org/10.1053/j.gastro.2011.12.061
- Furger KA, Menon RK, Tuck AB, et al (2001). The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med, 1, 621-32. https://doi.org/10.2174/1566524013363339
- Khodavirdi AC, Song Z, Yang S, et al (2006). Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res, 66, 883-8. https://doi.org/10.1158/0008-5472.CAN-05-2816
- Kim J, Ki SS, Lee SD, et al (2006). Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol, 101, 2051-9. https://doi.org/10.1111/j.1572-0241.2006.00679.x
- Korita PV, Wakai T, Shirai Y, et al (2008). Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol, 39, 1777-83. https://doi.org/10.1016/j.humpath.2008.05.006
- Lee HJ, Yeon JE, Suh SJ, et al (2014). Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut and liver, 8, 177-85. https://doi.org/10.5009/gnl.2014.8.2.177
- Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
- JM, Burroughs A, Bruix J (2003). Hepatocellular carcinoma. Lancet, 362, 1907-17. https://doi.org/10.1016/S0140-6736(03)14964-1
- Llovet JM, Di Bisceglie AM, Bruix J, et al (2008). Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst, 100, 698-711. https://doi.org/10.1093/jnci/djn134
- Nagoshi S (2014). Osteopontin: Versatile modulator of liver diseases. Hepatol Res, 44, 22-30. https://doi.org/10.1111/hepr.12166
- Rohde F, Rimkus C, Friederichs J, et al (2007). Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer, 121, 1717-23. https://doi.org/10.1002/ijc.22868
- Sakaki M, Makino R, Hiroishi K, et al (2010). Cyclooxygenase-2 gene promoter polymorphisms affect susceptibility to hepatitis C virus infection and disease progression. Hepatol Res, 40, 1219-26. https://doi.org/10.1111/j.1872-034X.2010.00727.x
- Shang S, Plymoth A, Ge S, et al (2012). Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology, 55, 483-90. https://doi.org/10.1002/hep.24703
- Sherman M (2011). Current status of alpha-fetoprotein testing. Gastroenterol Hepatol (N Y), 7, 113-4.
- Sieghart W, Wang X, Schmid K, et al (2011). Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol, 54, 89-97. https://doi.org/10.1016/j.jhep.2010.06.030
- Simao A, Madaleno J, Silva N, et al (2015). Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis, not for hepatocellular carcinoma screening. BMC gastroenterology, 15, 73. https://doi.org/10.1186/s12876-015-0307-1
- Singal A, Volk ML, Waljee A, et al (2009). Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther, 30, 37-47. https://doi.org/10.1111/j.1365-2036.2009.04014.x
- Sopipong W, Tangkijvanich P, Payungporn S, et al (2013). The KIF1B (rs17401966) single nucleotide polymorphism is not associated with the development of HBV-related hepatocellular carcinoma in Thai patients. Asian Pac J Cancer Prev, 14, 2865-9. https://doi.org/10.7314/APJCP.2013.14.5.2865
- Spangenberg HC, Thimme R, Blum HE (2006). Serum markers of hepatocellular carcinoma. Semin Liver Dis, 26, 385-90. https://doi.org/10.1055/s-2006-951606
- Taketa K (1990). Alpha-fetoprotein: reevaluation in hepatology. Hepatology, 12, 1420-32. https://doi.org/10.1002/hep.1840120625
- Tangkijvanich P, Hirsch P, Theamboonlers A, et al (1999). Association of hepatitis viruses with hepatocellular carcinoma in Thailand. J Gastroenterol, 34, 227-33. https://doi.org/10.1007/s005350050248
- Wan HG, Xu H, Gu YM, et al (2014). Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis. Clin Res Hepatol Gastroenterol, 38, 706-14. https://doi.org/10.1016/j.clinre.2014.06.008
- Wu CY, Wu MS, Chiang EP, et al (2007). Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut, 56, 782-9. https://doi.org/10.1136/gut.2006.109868
- Yuen MF, Lai CL (2005). Serological markers of liver cancer. Best Pract Res Clin Gastroenterol, 19, 91-9.
- Zhang CH, Xu GL, Jia WD, et al (2012). Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer, 130, 2685-92. https://doi.org/10.1002/ijc.26301
- Zhou C, Zhou HJ, Zhang XF, et al (2013). Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma. Ann Surg Oncol, 20, 929-37. https://doi.org/10.1245/s10434-012-2749-9
Cited by
- Human osteopontin: Potential clinical applications in cancer (Review) vol.39, pp.6, 2017, https://doi.org/10.3892/ijmm.2017.2964
- NRAGE is a potential diagnostic biomarker of hepatocellular carcinoma vol.97, pp.48, 2018, https://doi.org/10.1097/MD.0000000000013411
- Prognostic value of osteopontin in patients with hepatocellular carcinoma vol.97, pp.43, 2018, https://doi.org/10.1097/MD.0000000000012954